MedPath

A randomized controlled trial comparing the impact of continuous subcutaneous insulin infusion (CSII) therapy and multiple daily injection (MDI) regimens upon indices of behaviour, cognition and glycaemia in children and adolescents with type 1 diabetes.

Not Applicable
Completed
Conditions
Type 1 diabetes
Metabolic and Endocrine - Diabetes
Registration Number
ACTRN12610000605099
Lead Sponsor
The Royal Children's Hospital Melbourne
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
110
Inclusion Criteria

Youth aged 9-15.5 years with type 1 diabetes mellitus. Most children younger than 9 are unable or unwilling to use an MDI regimen, as this involves a lunchtime injection of insulin at school, which can be practically difficult for young children. Sixteen is the older end of the validated age range for the selected cognitive tests employed; therefore adolescents recruited at 15.5y will still be <16y at the end of study.

Naïve to CSII therapy

Currently using MDI regimen for at least 1 month duration

Previously assessed as suitable for CSII (by their own diabetes physician and care team) and already on the waiting list to commence CSII at their institution. This inclusion criterion is necessary as not all youth will be willing or deemed suitable to commence CSII (e.g. if not performing self monitoring of blood glucose levels at least 4 times / day).

Have access to an insulin pump device through private health insurance, self-pay or local loan scheme

Exclusion Criteria

Non-English speaking (as behavioural questionnaires and cognitive tests are conducted in English)

Co-existent developmental delay or pervasive neurological disorders such as autism that would interfere with a participant’s ability to perform psychometric testing

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Parental report of behaviour on the Behaviour Assessment System for Children- Second Edition (BASC-2) questionnaire[measured at 4 months.]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath